STOCK TITAN

Vanguard realigns holdings; Charles River (NYSE: CRL) shows 0% stake

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G/A

Rhea-AI Filing Summary

Charles River Laboratories International, Inc. Schedule 13G/A: The Vanguard Group reports 0 shares beneficially owned and 0% of common stock following an internal realignment. The filing explains certain Vanguard subsidiaries will report holdings separately in reliance on SEC Release No. 34-39538. The amendment is signed by the Head of Global Fund Administration on 03/26/2026.

Positive

  • None.

Negative

  • None.

Insights

Vanguard disaggregated its reporting and now reports no beneficial ownership in Charles River.

The filing documents an internal realignment at The Vanguard Group effective 01/12/2026, after which certain subsidiaries report holdings separately under SEC Release No. 34-39538. The statement clarifies that Vanguard no longer is deemed to beneficially own securities reported by those subsidiaries.

Cash‑flow treatment and any trading plans are not disclosed in the excerpt; subsequent filings by Vanguard subsidiaries may show holdings. Impact on Charles River's shareholder base depends on reported positions from those subsidiaries.






Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)




schemaVersion:


SCHEDULE 13G




Comment for Type of Reporting Person: On January 12, 2026, The Vanguard Group, Inc. went through an internal realignment. In accordance with SEC Release No. 34-39538 (January 12, 1998), certain subsidiaries or business divisions of subsidiaries of The Vanguard Group, Inc., that formerly had, or were deemed to have, beneficial ownership with The Vanguard Group, Inc., will report beneficial ownership separately (on a disaggregated basis) from The Vanguard Group, Inc. in reliance on such release. These subsidiaries and/or business divisions pursue the same investment strategies as previously pursued by The Vanguard Group, Inc. prior to the realignment. Further in accordance with SEC Release No. 34-39538 (January 12, 1998), The Vanguard Group, Inc. no longer has, or is deemed to have, beneficial ownership over securities beneficially owned by such subsidiaries and/or business divisions.


SCHEDULE 13G



The Vanguard Group
Signature:Ashley Grim
Name/Title:Head of Global Fund Administration
Date:03/26/2026

FAQ

What does the Schedule 13G/A filed by Vanguard for CRL state?

The filing states 0 shares beneficially owned and 0% ownership in Charles River Laboratories. It explains an internal realignment caused certain Vanguard subsidiaries to report holdings separately under SEC Release No. 34-39538.

When did Vanguard's internal realignment take effect in the filing?

The filing references the internal realignment effective 01/12/2026. It says subsidiaries now report disaggregated beneficial ownership in reliance on SEC Release No. 34-39538 after that date.

Who signed the Schedule 13G/A amendment for Vanguard for CRL?

The amendment is signed by Ashley Grim, Head of Global Fund Administration, dated 03/26/2026. The signature block appears at the end of the filed excerpt.

Does the filing show any voting or dispositive power for Vanguard over CRL shares?

No. The filing lists 0 for sole and shared voting power and 0 for sole and shared dispositive power, indicating no reported control or disposition authority over Charles River common stock.

Will this filing change Charles River's public shareholder count or control?

The filing documents reporting changes by Vanguard but lists 0 shares owned by The Vanguard Group. Any change to the public shareholder mix depends on separate reports from Vanguard subsidiaries; this amendment itself reports no Vanguard ownership.
Charles Riv Labs Intl Inc

NYSE:CRL

View CRL Stock Overview

CRL Rankings

CRL Latest News

CRL Latest SEC Filings

CRL Stock Data

8.13B
48.67M
Diagnostics & Research
Services-commercial Physical & Biological Research
Link
United States
WILMINGTON